Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

Heine A; Schwab K.S; Brossart P; Kristiansen G; Held S.E.A; Schild H.H

首页> 外文期刊>Case Reports in Oncology >Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

【24h】

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

机译：Nivolumab和Ipilimumab成功治疗难治性头颈部鳞状细胞癌

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Treatment options for patients with platinum-refractory, recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited, and prognosis is poor. Nivolumab (Opdivo) has been approved by the US Food and Drug Administration (FDA) for the trea

机译：铂类难治性，复发性，转移性头颈部鳞状细胞癌（HNSCC）患者的治疗选择有限，预后差。 Nivolumab（Opdivo）已获得美国食品和药物管理局（FDA）的批准

著录项

来源
《Case Reports in Oncology》 |2018年第1期|共页
作者
Heine A; Schwab K.S; Brossart P; Kristiansen G; Held S.E.A; Schild H.H;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类临床医学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer [J] . Walter Urba, Bartosz Chmielowski, Deryk Loo, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：MGA271联合ipilimumab在B7-H3表达黑素瘤，头颈部鳞状细胞癌或非小细胞肺癌患者中进行的I期开放标签剂量递增研究
2. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck [J] . Cocks Kim, Contente Marta, Simpson Sarah, PharmacoEconomics . 2019,第8期

机译：一种Q-Twist分析比较Nivolumab和治疗调查员在颈部复发/转移铂 - 难治鳞状细胞癌患者中的选择
3. ANALYSES OF HEALTHCARE RESOURCE UTILIZATION (HCRU) IN CHECKMATE 141, A PHASE 3 STUDY OF NIVOLUMAB VERSUS INVESTIGATOR'S CHOICE (IC) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) PLATINUM-REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) [J] . DeRosa M., Cocks K., Taylor F., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：患有医疗资源利用率（HCRU）的治疗方法141，患有复发性或转移性（R / M）铂 - 牙髓耐火鳞状细胞癌患者的Nivolumab与调查员选择（IC）的第3阶段研究（SCCHN）
4. Survival prediction of squamous cell head and neck cancer patients based on radiomic features selected from lung cancer patients using artificial neural network [C] . H. Kamezawa, H. Arimura, M. Soufi SPIE Medical Imaging Conference . 2018

机译：利用人工神经网络从肺癌患者的放射学特征中预测鳞状细胞癌的生存率
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. [D] . 野﨑, 結 2019

机译：PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
6. Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab [O] . Katjana S. Schwab, Glenn Kristiansen, Hans H. Schild, 2018

机译：Nivolumab和Ipilimumab成功治疗难治性头颈部鳞状细胞癌
7. Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab [O] . Katjana S. Schwab, Glenn Kristiansen, Hans H. Schild, 2018

机译：用Nivolumab和Ipilimumab成功治疗头颈部难治性鳞状细胞癌

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab

摘要

著录项

相似文献

相关主题

期刊订阅